Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPHT IVERIC bio (OPHT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About IVERIC bio Stock (NASDAQ:OPHT) 30 days 90 days 365 days Advanced Chart Remove Ads Get IVERIC bio alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.13▼$1.3952-Week Range N/AVolumeN/AAverage Volume159,109 shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.Read More… Remove Ads Receive OPHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address OPHT Stock News HeadlinesGossamer Bio Inc GOSSNovember 5, 2023 | morningstar.comIveric Bio ticks higher as it sees sale to Astellas closing July 11June 30, 2023 | msn.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.March 31, 2025 | Altimetry (Ad)Iveric Bio falls amid concern about Astellas dealJune 29, 2023 | msn.comBaird Downgrades IVERIC bio (ISEE)May 6, 2023 | msn.comApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioMay 6, 2023 | msn.comIveric Bio (NASDAQ:ISEE) Sold for $5.9BMay 2, 2023 | msn.comAstellas to Buy Eye-Drug Maker Iveric Bio for $5.9 BillionMay 1, 2023 | msn.comSee More Headlines OPHT Stock Analysis - Frequently Asked Questions How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:OPHT) issued its earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.02. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), Meta Platforms (META) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings10/31/2018Today3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OPHT CIK1410939 Webwww.ophthotech.com Phone(212) 845-8200FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$63.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.53% Return on Assets-41.88% Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09 Sales & Book Value Annual Sales$209.98 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / BookN/AMiscellaneous Outstanding Shares41,420,000Free FloatN/AMarket Cap$1.65 billion OptionableOptionable Beta1.49 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OPHT) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IVERIC bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
